Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.66 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.62 |
| ▸ | FAAH | O00519 | 2/20 | 0.62 |
| ▸ | GPX4 | P36969 | 1/20 | 0.61 |
| ▸ | CDK4 | P11802 | 3/20 | 0.58 |
| ▸ | CCND1 | P24385 | 3/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28468258 | 0.90 | MAPT (0.77) | MAPTLMNABAZ2BTRPV1FAAH | |
| SCHEMBL969392 | 0.90 | TRPV1 (0.72) | MAPTLMNABAZ2BTRPV1FAAH | |
| SCHEMBL6492381 | 0.87 | CDK4 (0.63) | MAPTLMNABAZ2BTRPV1FAAH | |
| SCHEMBL28929350 | 0.81 | SIGMAR1 (0.60) | TRPV1FAAHGPX4 | |
| SCHEMBL3079170 | 0.80 | MAPT (0.71) | MAPTLMNABAZ2BCDK4CCND1 | |
| SCHEMBL6335099 | 0.80 | CDK4 (0.76) | TRPV1FAAHGPX4CDK4CCND1 | |
| SCHEMBL6474214 | 0.80 | LMNA (0.60) | MAPTLMNABAZ2BTRPV1FAAH | |
| SCHEMBL6200573 | 0.80 | HTR6 (0.57) | MAPTLMNABAZ2BTRPV1 | |
| SCHEMBL14015615 | 0.79 | MAPT (0.75) | MAPTLMNABAZ2BGPX4TAAR1 | |
| SCHEMBL16462808 | 0.79 | MAPT (0.75) | MAPTLMNABAZ2BGPX4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | disclosed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | disclosed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-6583135-B2 | Treating central nervous system disorders wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). | PHARMACIA & UPJOHN COMPANY | 2003-06-24 | — | — | US | disclosed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | MAPT 2666/4885LMNA 4162/4885BAZ2B 3100/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | MAPT 2537/4885LMNA 4136/4885BAZ2B 3155/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | MAPT 2666/4885LMNA 4162/4885BAZ2B 3100/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | MAPT 2537/4885LMNA 4136/4885BAZ2B 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.